-

Longhorn Vaccines and Diagnostics to Present at The Allen D. Leman Swine Conference

BETHESDA & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics LLC, a One Health and One World company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today announced that Jerry Torrison, DVM, PhD, Senior Vice President of Animal Health, will present at the Allen D. Leman Swine Conference, being held in the St. Paul River Center, Minnesota, on Sept. 17 – 20, 2022.

Dr. Torrison will be giving the Morrison Lectureship, named in honor of Dr. Bob Morrison, his PhD advisor, for his work in the areas of swine disease epidemiology and factors that drive economics and productivity in the swine industry.

Presentation Title: FADs,..Are We Ready (Together)?
Presenter: Jerry Torrison, DVM, PhD, Senior Vice President of Animal Health at Longhorn Vaccines and Diagnostics
Abstract Title: Foreign Animal Disease (FAD) Response
Session Date: Sept. 20, 2022
Session Time: 9:00 – 10:00am CST
Session Location: The St. Paul River Centre, Minnesota

About Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines and Diagnostics LLC is a One Health company based in Maryland that is developing vaccines and diagnostic tools for worldwide public health concerns and to prevent future pandemics. Since its inception in 2006, Longhorn has focused on developing vaccines and diagnostic tools that can impact a pandemic on a global scale and at all socio-economic levels. Since pandemics flow between humans and animals, Longhorn caters to both in order to surveil, diagnose, prevent and treat the next infectious disease.

Longhorn’s core product, PrimeStore® Molecular Transport Medium (MTM), is a patented, FDA cleared, state-of-the-art ambient temperature molecular diagnostic collection and transport device that can help governments, global health organizations, and drug manufacturers improve the diagnosis and treatment of highly infectious diseases such as Influenza, SARS-CoV-2, and Mycobacterium tuberculosis (TB). Unlike standard devices for collecting and transporting virus samples, PrimeStore® MTM is the first molecular transport device that can safely deactivate pathogens and stabilize RNA and DNA, allowing enhanced point of care and ambient temperature transport for laboratory based molecular testing and characterization.

Contacts

Longhorn Vaccines and Diagnostics LLC
Jeffrey Fischer
Email: jeff@lhnvd.com

Media
Alexis Feinberg – ICR Westwicke PR
Email:  LonghornPR@icrinc.com

Longhorn Vaccines and Diagnostics LLC


Release Versions

Contacts

Longhorn Vaccines and Diagnostics LLC
Jeffrey Fischer
Email: jeff@lhnvd.com

Media
Alexis Feinberg – ICR Westwicke PR
Email:  LonghornPR@icrinc.com

More News From Longhorn Vaccines and Diagnostics LLC

Longhorn Vaccines and Diagnostics to Present New Data on DRG5‑BD11 Showing Broad Activity Against Multiple Bacterial Classes at ESCMID 2026

BETHESDA, Md. & GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced it will present new preclinical data demonstrating that DRG5‑BD11, a novel human bispecific IgM monoclonal antibody, exhibits broad antibacterial activity against gram‑positive bacteria, gram‑negative bacteria, and mycobacteria, underscoring its potential as a new strategy to address antimicrobial resistance (AMR) and sepsis during a pos...

Longhorn Vaccines and Diagnostics Presents New Preclinical Data on Broad-Spectrum Anti-Bacterial Monoclonal Antibody LHNVD-501

WASHINGTON--(BUSINESS WIRE)--Longhorn Vaccines and Diagnostics (LHNVD), an IND enabling-stage biopharmaceutical company, today announced new preclinical data for LHNVD-501, a half-life extended humanized monoclonal antibody targeting peptidoglycan (PGN), a structural component present in virtually all bacterial pathogens. By targeting PGN, an upstream driver of sepsis, metabolic disease, autoimmune disorders, and neurodegeneration, LHNVD-501 may address the underlying inflammatory causes of the...

Longhorn Vaccines & Diagnostics' PrimeStore® MTM Validated with New Data for Large-Scale, Global TB Screening

GAITHERSBURG, Md.--(BUSINESS WIRE)--Longhorn Vaccines & Diagnostics (“Longhorn”), a One Health company developing antibodies and diagnostic tools for global public health and zoonosis concerns, today announced compelling new data validating the utility of various swab samples processed with PrimeStore® MTM for tuberculosis (TB) detection in both pediatric clinical settings and large-scale community screening. The findings were divided into two presentations and presented by TB and viral inf...
Back to Newsroom